Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.1%

14 terminated/withdrawn out of 93 trials

Success Rate

80.3%

-6.3% vs industry average

Late-Stage Pipeline

29%

27 trials in Phase 3/4

Results Transparency

70%

40 of 57 completed trials have results

Key Signals

14 recruiting40 with results10 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
38(42.7%)
Phase 1
23(25.8%)
Phase 3
22(24.7%)
Phase 4
5(5.6%)
N/A
1(1.1%)
89Total
Phase 2(38)
Phase 1(23)
Phase 3(22)
Phase 4(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (93)

Showing 20 of 93 trials
NCT07288320Phase 2Recruiting

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

Role: lead

NCT06966401Phase 3Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT07196501Phase 3Recruiting

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT07288333Phase 2Recruiting

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Role: lead

NCT06267846Phase 2Completed

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Role: lead

NCT07611786Not Yet Recruiting

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

Role: collaborator

NCT06963021Phase 3Recruiting

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT07365462Phase 2Recruiting

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Role: lead

NCT06312189Phase 3Enrolling By Invitation

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Role: lead

NCT04400331Phase 3Completed

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Role: lead

NCT07105111Phase 4Recruiting

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Role: lead

NCT07187375Phase 2Active Not Recruiting

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Role: lead

NCT07111988Phase 2Not Yet Recruiting

Valbenazine in Obsessive Compulsive Disorder

Role: collaborator

NCT07114874Phase 3Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Role: lead

NCT07227818Phase 3Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Role: lead

NCT05226780Phase 2Terminated

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Role: lead

NCT07105098Phase 3Recruiting

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Role: lead

NCT04490915Phase 3Active Not Recruiting

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

Role: lead

NCT05206513Phase 3Completed

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Role: lead

NCT07536269Phase 2Not Yet Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Role: lead